In the United States, doctors often prescribe a low daily dose of aspirin to people between 50 and 70 years, to avoid beverages and tensions, even if they have never had any related diseases.
In Europe, cardiologists do this only after the first problem of the heart.
Aspirin flows the blood and prevents clonics to form in the arteries. But too thin blood can cause hemorrhage. Therefore the dilemma: What kind of patients do the benefit of reducing cardiovascular risk over the risk of hemorrhage?
For people who have already had a blow or a heart attack, the balance is clearly inclined to taking aspirin, according to many studies. These people have a clear risk of second accident, and aspirin helps to prevent it.
New study, published in the Newspaper of the American Medical Association (Jamao), The It offers a broader vision for patients who have not yet had cardiovascular problems.
But it really does not solve the controversy: it says that on the one hand aspirin reduces the risk of heart attack and striking in people without history; but, on the other hand, it increases the risk of severe bleeding, especially in the brain, stomach and intestines.
Aspirin does not have an impact on mortality in one way or the other.
"For healthy people, the low benefits of aspirin to prevent blow and coating have a counterpart in increased risk of bleeding"says Jane Armitage, a professor of epidemiology at the University of Oxford.
As a conclusion, then, Doctors should recommend aspirations according to a case, depending on the other risks of the patient, writes the cardologist Michael Gaziano in a commentary.
For example, stopping smoking or decreasing cholesterol levels are other methods to try to reduce the cardiovascular risk.
This new study is a meta-analysis, which means that the two King & College London's students studied the 13 most important clinical trials on the subject from 1988 to 2018 and concluded on all these tests.
This method enables eliminating the uncertainties associated with each study and identifying a general general impact, based on 164,000 people who participated in the tests altogether.
The surprise is that researchers found no link between aspirin and the reduction of cancer, contrary to what more and more studies showed that aspirin reduced the risk of certain cancers, especially heart cancer.
So much that the US Preventive Services Working Group (US Preventive Services Task Force), a body that issues public health recommendations, advocates from 2016 for daily intake aspirations in people from 50 to 69 years, among other things, reduce the impact of this cancer.